Algoritmo terapeutico nel paziente recidivato-refrattario nel linfoma mantellare

Bibliografia

1. Stratificazione del rischio e unmet needs nel linfoma mantellare

– Silkenstedt E, Dreyling M. Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approaches. Hematol Oncol. 2023 Jun;41 Suppl 1:36-42.
– Lew TE, et al. Treatment approaches for patients with TP53-mutated mantle cell lymphoma. Lancet Haematol. 2023 Feb;10(2):e142-e154.
– Scheubeck G, et al. Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression). Leukemia. 2023 Sep;37(9):1887-1894.

2. Cambiamenti nell’algoritmo terapeutico del paziente con linfoma mantellare in prima linea: chemioterapia + novel agents e approcci chemo-free

– Martin Dreyling, at al. Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network. Blood 2022; 140 (Supplement 1): 1–3
– Wang ML, et al. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med. 2022 Jun 30;386(26):2482-2494
– Carlo Visco, et al. Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL). Blood 2023; 142 (Supplement 1): 737
– Anita Kumar, et al. A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma. Blood 2023

3. Novità nell’algoritmo terapeutico nel paziente con linfoma mantellare recidivato e refrattario: strategie nei pazienti refrattari a ibrutinib

– Wang M, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020 Apr 2;382(14):1331-1342
– Wang M, et al. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol. 2023 Jan 20;41(3):555-567.
– Wang ML, et al. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol. 2023 Aug 20;41(24):3988-3997.
– Jonathon B. et al. Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study. Blood 2023; 142 (Supplement 1): 981.

4.     Ruolo del trapianto autologo in prima remissione e in salvataggio

– Michael Wang, et al. Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study. Blood 2023; 142 (Supplement 2): LBA–2.

5. Novità nell’algoritmo terapeutico nel paziente con linfoma mantellare recidivato e refrattario: anticorpi bispecifici

– Tycel J. et al. Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma. Blood 2022; 140 (Supplement 1): 178–180.
– Tycel J. et al. A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma. Blood 2023; 142 (Supplement 1): 3052